Effect of Infliximab on treatment of cirrhosis.
Phase 2
- Conditions
- Cryptogenic cirrhosis.Other and unspecified cirrhosis of liver
- Registration Number
- IRCT2016052228003N1
- Lead Sponsor
- Research center for infectious diseases of digestive system, research adjutancy of Ahvaz Jundishapur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
existence of proved cryptogenic cirrhosis; lack of experience with infliximab treatment in cirrhosis due to it; having informed consent
Exclusion criteria: Decompensated cirrhosis; active or latent tuberculosis; patient's trend to leaving the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of MELD score. Timepoint: 0- 3th month- 6th month. Method of measurement: according to creatinine, billirubine, and INR- Range: 6-40.
- Secondary Outcome Measures
Name Time Method Decrease of numbers of hospitalization and decrease of cirrhosis complications. Timepoint: 0- 3th month- 6th month. Method of measurement: Evaluation of patient's medical file and disease progression.